Sushmita Chanda, PhD, DABT

Sushmita Chanda, PhD, DABT has extensive work experience in the field of translational safety sciences and preclinical development. Sushmita is currently employed at Aligos Therapeutics as the EVP, Translational Safety Sciences since August 2018. Prior to this, they held the position of VP, Preclinical Development at Alios BioPharma, a Johnson and Johnson Company, from February 2010 to July 2018.

From 2000 to 2010, Dr. Chanda worked at Roche Palo Alto, first as the Director of Toxicology, Non Clinical Safety from January 2000 to April 2009, and then as the Sr. Director and Head of Non Clinical Safety from an unknown start date to 2010.

Before joining Roche Palo Alto, they worked as a Toxicologist at Sugen Inc from an unknown start date to 2000.

Sushmita Chanda, PhD, DABT has an extensive education history in the field of toxicology. Sushmita obtained their Ph.D. in Toxicology and Pharmacology from the University of Louisiana Monroe, where they studied from 1990 to 1995. Following this, they pursued post-doctoral training at the University of North Carolina at Chapel Hill, specializing in Toxicology from 1995 to 1998. In addition to their formal education, Sushmita Chanda has also obtained the certification of Diplomate of the American Board of Toxicology from the American Board of Toxicology, Inc. in January 2021.